Recruiting

Dragonfly™ Scope

Sponsor:

University of Colorado, Denver

Code:

NCT07120295

Conditions

Bile Duct Adenocarcinoma

Bile Duct Carcinoma

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Dragonfly™ Digital Pancreaticobiliary System

Study Details

Brief summary:

This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures. The purpose of this research is to assess whether the Dragonfly™ Pancreaticobiliary Scope functioned as intended in combination with the commercially available accessories during your scheduled endoscopy procedure. This includes achieving stone fragmentation of difficult biliary stone(s) while obtaining adequate tissue specimens for analysis. There will also be a Product performance evaluation as rated by the endoscopist operating the DPS System and evaluation of ergonomics and usability.

Conditions

Bile Duct Adenocarcinoma

Bile Duct Carcinoma

Study ID

NCT07120295

Start date

Aug 11, 2025

Status verified date

Sep, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Provision to sign and date the consent form;
2. Adult patients ≥ 21 years old;
3. Any patient who is required to undergo endoscopic retrograde cholangiopancreatography (ERCP) procedure with the clinical need to perform cholangioscopy for:

1. Indeterminate biliary stricture, or
2. Failed biliary stone extraction with conventional techniques.
4. Willing and able to follow study procedures and comply with study follow-up.

Exclusion Criteria:

1. Pregnancy or lactation;
2. Surgically or physiologically altered GI anatomy that precludes advancement of the duodenoscope for biliary cannulation;
3. Patients on anti-coagulants and anti-platelet medications that cannot be withheld pre-procedure, except for aspirin, 81mg;
4. Coagulopathy (INR > 1.8) or thrombocytopenia (Platelets < 50,000) that is not correctable and felt to be a contraindication to proceeding with biopsy or lithotripsy per the treating endoscopist;
5. Active suppurative cholangitis with evidence of purulent drainage at the time of papilla visualization;
6. Patients who are not candidates for anesthesia to permit ERCP.

Study Design

Enrollment

75 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Interventional Group

Interventions

Dragonfly™ Digital Pancreaticobiliary System

Dragonfly™ Digital Pancreaticobiliary System is indicated for use in the direct visualization of the biliary and pancreatic ducts for diagnostic and therapeutic interventions during endoscopic procedures. DPS is a single-use device that serves as an access and delivery catheter used with a proprietary DDC. The DDC is intended to control auto-illumination, and process images from the DPS for diagnostic and therapeutic applications during endoscopic procedures in the pancreaticobiliary system including the hepatic ducts.

Primary outcome measure

  • Stone Fragmentation- Clearing of Biliary Stones [ Time Frame: Up to 6 months ]
  • Tissue Acquisition during endoscopy procedure [ Time Frame: Up to 6 months ]

Central Contacts and Locations

Central contacts

Locations

Universtiy of Colorado Hospital

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Sandra Boimbo DART Program Director

303-724-8892SANDRA.BOIMBO@CUANSCHUTZ.EDU

Principal Investigator:

Raj Shah, MD

More Information

Sponsor

University of Colorado, Denver

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Colorado, Denver on 2026-09-03.